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Abstract 
Background: Cirrhosis and acute-on-chronic liver failure (ACLF) are associated with systemic 
inflammation, and caspase-mediated hepatocyte cell death. Emricasan is a novel, pan-caspase inhibitor. 
Aims of this study were to assess the pharmacokinetics, pharmacodynamics, safety and clinical 
outcomes of Emricasan in acute decompensation (AD) of cirrhosis.   
 
Methods: This was a phase 2, multicentre, double-blind, randomized trial. The primary objective was 
to evaluate the pharmacokinetics, pharmacodynamics and safety of Emricasan in patients with cirrhosis 
presenting with AD and organ failure. AD was defined as an acute decompensating event ≤6 weeks’ 
duration. Patients were randomised proportionately to Emricasan 5mg bid, Emricasan 25mg bid, 
Emricasan 50mg bid or placebo. Treatment was continued to 28 days, or voluntary discontinuation. 
Participants: Twenty-three subjects were randomized, of whom 21 were dosed (placebo n=4; 5mg 
n=5; 25mg n=7; 50mg n=5). Pharmacokinetic data showed 5mg dose was associated with low plasma 
levels (<50ng/ml), and 25mg and 50mg doses showed comparable pharmacokinetic profiles. Therefore, 
for analysis of secondary endpoints, placebo and 5mg groups were merged into a ‘placebo/low-dose’ 
group, and 25mg and 50mg groups were merged into a ‘high-dose’ group. Five deaths occurred 
amongst the 21 patients, all due to progression of liver disease (2 in placebo/low-dose, 3 in high-dose). 
No statistically significant changes from baseline MELD score or CLIF-C ACLF score were noted 
between placebo/low-dose and high-dose groups at day 7 (MELD -1 vs -1, CLIF-C ACLF 0.7 vs 0.8). 
An initial reduction in cleaved keratin M30 fragment was noted between placebo/low-dose and high-
dose groups (Percent relative change: day 2: -11.6 vs -42.6, p=0.017, day 4: -3.5 vs -38.9 p=0.017) 
although this did not persist to day 7 (-3.1 vs -20.8, p=0.342). 
Interpretation: This study demonstrates that Emricasan is safe and well tolerated in advanced liver 
disease. However, this study fails to provide proof-of-concept support for caspase inhibition as a 
treatment strategy for ACLF.  
 
Trial registration: EudraCT 2012-004245-33 




The natural history of cirrhosis is characterised by progression to episodes of acute decompensation 
(AD) of liver function(1). Most patients with cirrhosis and AD are treated successfully in the majority 
of cases. However, about 30% of these patients develop hepatic and/or extra-hepatic organ failure that 
progresses in about 20% to multi-organ failure and death(2). When this occurs rapidly, within a period 
of weeks, the condition is referred to as acute-on-chronic liver failure (ACLF). The 170,000 cirrhosis 
deaths in Europe each year are largely due to ACLF and the condition costs $3Bn in the USA and 
£50K per survivor in the UK(3). There are as yet no specific therapies for ACLF. 
 
The pathobiology of ACLF is characterized by hepatic and systemic inflammation, and progressive, 
unrelenting hepatocyte injury and death(4, 5). Approaches targeting systemic inflammation have been 
tried, such as anti-TNF therapies, although these have led to negative outcomes suggesting that 
alternative approaches are required(6). 
 
Apoptosis is a highly regulated form of or programmed cell death. In response to injury or 
inflammation, hepatocytes can undergo apoptosis via an extrinsic pathway activated by death ligands, 
Fas, and tumour necrosis factor- related apoptosis-inducing ligand (TRAIL), or an intrinsic pathway 
activated by intracellular stress of membrane-bound organelles, such as lysosomes, endoplasmic 
reticulum and mitochondria(7-10). Both pathways of apoptosis converge on the caspases (cysteine 
aspartyl proteases), which play an essential role in the initiation, execution and regulation of 
apoptosis(11).  
 
Previous work has demonstrated that apoptosis is a key pathway of cell death in patients with ACLF. 
Fragmented chromatin and caspase-dependent cleaved keratin 18 are both terminal end-products of the 
apoptotic pathway(12). Adebayo et al have shown that serum levels of cleaved keratin 18 (M30 
fragment) are significantly elevated in patients with ACLF compared to patients with AD alone, and 
correlate with disease severity(13). Immunohistochemistry of liver tissue also demonstrates apoptotic 
M30-positive hepatocytes in patients with severe ACLF. Similarly, Cao et al have demonstrated 
elevated levels of fragmented chromatin in the ACLF compared with the AD group(14). These data 
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support the central role of hepatocyte apoptosis in the progression of ACLF, and provide the rationale 
for therapeutic targeting of apoptosis in ACLF.   
 
Caspases provide a druggable target for the inhibition of apoptosis in liver disease. As such, caspase 
inhibitors have been shown to decrease liver injury in rodent models of acute liver failure, fatty liver 
disease, cholestatic liver injury and alcohol-induced liver injury(15-20).  
 
Emricasan (IDN-6556) is a novel, orally active, pan-caspase protease inhibitor. Emricasan has been 
studied in eight phase 1 studies and eight phase 2 studies involving over 650 patients, providing initial 
safety data and supporting the dose range of 5-50mg used in phase 2 studies in patients with chronic 
liver disease(21, 22). The aims of this study were to assess the pharmacokinetics, pharmacodynamics, 
safety and clinical outcomes of Emricasan in patients with cirrhosis and a rapid deterioration of liver 
function associated with organ failure.   
 
 
Patients and Methods 
Study IDN-6556-02 (ClinicalTrials.gov NCT01937130) was conducted in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent was obtained 
from all patients before enrolment, in agreement with approved protocols from research ethics 
committees (North West-Haydock Research Ethics Committee, reference 13/NW/0464).  
 
Study design: This was a phase 2, multicentre, double-blind, randomized trial was conducted in 10 
sites in the United States and United Kingdom. The primary objective was to evaluate the 
pharmacokinetics, pharmacodynamics and safety of emricasan, orally administered for 28 days in 
patients with cirrhosis and a rapid deterioration of liver function associated with organ failure (figure 
1).  
 
Selection of doses:  The relationship between emricasan dose and biomarker responses had been 
thoroughly characterized in subjects with active HCV hepatitis and normal hepatic function(21,22). 
However, the dose-biomarker response relationship had not been characterized in subjects with 
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impaired hepatic function.  The initial studies in subjects with HCV hepatitis and normal function 
assessed the effect of emricasan upon a panel of 4 biomarkers (caspase 3/7, M30, ALT and AST) at 
oral doses ranging from 0.5 mg BID up to 200 mg BID.  Doses as low as 0.5 mg BID dose were 
pharmacodynamically active, decreasing M30 and ALT by nearly 50%, but had less effect upon AST 
and caspase 3/7.  Doses greater than 50 mg BID did not appear to have any greater reduction in the 4 
biomarkers compared to the 50 mg BID dose.  Thus, doses of 5, 25 and 50 mg BID were selected for 
this study in patients with severe hepatic impairment. 
Sample size:  The sample size was based around a simulation exercise of 1000 simulated outcomes, 
which were used to predict the dose required for a set target exposure. A sample size of 15 subjects per 
group (60 total) would have resulted in >80% of simulated outcomes recommending the correct dose to 
take forward to a follow-on ACLF efficacy study, if the exposure and pharmacodynamic effects in 
cirrhotic subjects from this study were similar to that observed in subjects with active HCV hepatitis 
and normal hepatic function previously studied (data modelled from Pockros et al.(21) and Shiffman et 
al.(22)). 
Inclusion criteria: Eligible patients included those 18 years of age or older, with stable compensated 
or decompensated cirrhosis, presenting with an acute deterioration of liver function and associated 
organ failure. Cirrhosis was diagnosed by clinical, radiological and/or histological means. An acute 
deterioration of liver function was defined as an acute decompensating event or illness of ≤ 6 weeks’ 
duration, on the background of cirrhosis (see definitions below).  
 
Exclusion criteria: recent hospital admission (within 4 weeks) for a complication of cirrhosis, greater 
than two-organ failure, HIV infection, uncontrolled bacterial infection, pre-existing chronic kidney 
disease, autoimmune liver disease, active malignancy aside from hepatocellular carcinoma, need for 
mechanical ventilation, inability to obtain consent, and haemodynamic instability (including use of 
inotropes, aside from terlipressin for hepatorenal syndrome). 
 
Definitions: Criteria for organ failure used in this study were: 
Liver: bilirubin ≥ 12.0 mg/dL 
Kidney: creatinine ≥ 2.0 mg/dL 
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Cerebral: hepatic encephalopathy West Haven grade III or IV 
Coagulation: INR ≥ 1.7 
 
In terms of organ failure, eligibility for this study was on the basis of one of the following: (i) renal 
failure (defined as creatinine ≥ 2.0 to ≤ 3.4 mg/dL); (ii) other single organ failure with a) renal 
impairment (defined as an increase in creatinine of > 0.3 mg/dL from an established baseline level) 
and/or b) hepatic encephalopathy grade I or II; (iii) two organ failures. As noted above, patients with 
respiratory failure requiring mechanical ventilation, and circulatory failure requiring inotropic support, 
were excluded. Additionally, MELD score and CLIFC-ACLF score were calculated as previously 
described(23, 24). 
 
Treatment and Randomisation: The Sponsor, investigational staff and subjects were all blinded to 
the treatment group assignment. Patients were randomised proportionately into four groups: emricasan 
5mg bid, emricasan 25mg bid, emricasan 50mg bid and matching placebo bid through the study’s 
Interactive Web Response System.  The randomization schedule was generated using a validated 
randomization program and verified for accuracy using quality control procedures. Treatment was 
continued for 28 days in all four groups. Randomisation was stratified on the basis of a positive alcohol 
history, and also prior steroid use. A positive alcohol history was defined as ongoing alcohol use up 
until the time of entry into the study. Treatment was continued for 28 days unless the patient 
voluntarily discontinued treatment.  
 
Haematology, Biochemistry and Biomarkers: Routine haematology and biochemistry parameters 
were monitored, as well as blood tests for pharmacokinetic and biomarker evaluations. 
Pharmacokinetic studies were performed at day 1 and day 4 following initiation, and serum biomarkers 
of apoptosis (cleaved keratin 18 (M30 Apoptosense®; Peviva, West Chester, OH, USA and full-length 
keratin 18 (M65®; Peviva, West Chester OH, USA) were also collected at days 1, 2, 4 and 7. Follow-




Statistics: Statistical analyses of the change from Baseline in M30, M65, M30/M65 ratio, MELD and 
CLIF-C ACLF score were conducted using an analysis of covariance (ANCOVA) adjusted for 
baseline.  Given the distribution of data, M30 and M65 were log-transformed prior to analysis and 
results were back-transformed to provide a relative percent change from baseline.  No adjustments for 
multiple comparisons were made. Associations between changes in cell death biomarkers and efficacy 
endpoints were assessed using Pearson’s correlation coefficient.  
The decision to pool the placebo and 5 mg emricasan for purposes of efficacy analyses was made after 
the premature termination of the study and unblinding.  The goal of pooling those groups was to 
increase the number of subjects for summary purposes.  The justification for pooling was that the 5 mg 




Patients: Between 22 January 2014 and 17 September 2014, 23 subjects were randomized into this 
study, of whom 21 were dosed (placebo n=4; emricasan 5 mg bid n=5; emricasan 25 mg bid n=7; 
emricasan 50 mg bid n=5) at 10 sites. The study was stopped once adequate pharmacokinetic samples 
had been obtained since the study was slow to recruit. The CONSORT diagram is presented in figure 2. 
Baseline characteristics of these patients by individual randomized treatment group is presented in 
Supplementary Table 1. 
Emricasan pharmacokinetics: A summary of the key pharmacokinetic data is presented in Table 1. 
The geometric means of the emricasan AUC0-8, Cmax, and AUC0-last increased in an approximately dose-
proportional manner between the 5 mg and 50 mg doses on day 1 and day 4. No plasma accumulation 
was apparent in any of the treatment arms on day 4 compared to day 1. Generally, lower between-
subject variability was observed in all PK parameters in the lower dose treatment arms than in the 50 
mg arm, with coefficients of variation (CVs) ranging from 28% to 48% in the IDN-6556 5 mg and 25 
mg groups, and from 99% to 258% in the IDN-6556 50 mg group.   
Biomarker responses: Changes in the keratin fragment M30 (mean+/-SD) and caspase 3/7 (mean+/-
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SD) are shown in Figure 3.  In this study, changes in caspase 3/7 activity (Figure 3b), rather than M30 
levels (Figure 3a), were a more sensitive indicator of emricasan pharmacodynamic activity.  The 
placebo and 5 mg groups had no significant effect upon M30 levels on any study day, although there 
was a trend towards reduction in M30 with the 25mg and 50mg doses between days 2 and 4. Caspase 
3/7 activity also showed a non-significant trend in reduction with the 25mg and 50mg doses by the day 
2 visit and throughout the initial 7 days of the study, while the placebo and 5mg dose had no effect 
(Figure 3b).  Since the 5 mg emricasan group had no detectable pharmacodynamic effect, the placebo 
and 5 mg groups were merged into a ‘placebo/low-dose’ group, and the 25mg and 50mg groups were 
merged into a ‘high-dose’ group.  A statistically significant decrease in log-transformed M30 at day 2 
and day 4 was noted between the placebo/low-dose and high-dose groups.  These results were back-
transformed to provide percent relative change from Baseline (Day 2: -11.6 vs -42.6, p=0.017, Day 4: -
3.5 vs -38.9 p=0.017). The direction of treatment effect remained in favour of the high-dose group at 
Day 7; however this was not statistically significant (-3.17 vs -20.8, p=0.342). No statistically 
significant differences between the high-dose and placebo/low dose were seen for the change from 
baseline in log-transformed M65 at any time point up to day 7.  No consistent correlations were seen 
across timepoints in associations between changes in cell death biomarkers, caspase 3/7 activity and 
efficacy endpoints.  
Patient Outcomes: As evident in the CONSORT diagram (Figure 2), of the 21 subjects dosed, 7 
completed 28 days of administration. Of the remaining 14 patients, 3 died as a consequence of their 
liver disease and 6 were lost to follow-up. The patient baseline characteristics, summarised by the 
placebo/low-dose and high-dose groups, are presented in Tables 2 and 3. No significant differences in 
demographics were noted between the two groups. All patients, bar one, had alcohol-related liver 
disease (ARLD). The majority of patients (81%) had ACLF present at baseline. Alcohol was identified 
as a precipitant for the rapid deterioration in liver function in all cases aside from two (one in the low 
dose group and one in the high dose group). Bacterial infection was identified as a further precipitant in 
29% of cases. No significant differences in severity of liver disease at baseline were noted, as assessed 
by MELD score or CLIF-C ACLF score (where ACLF was present). 
Patient disposition and mortality are presented in Figure 2. A total of 5 deaths occurred amongst the 21 
patients dosed during the study period, although 2 deaths were after completion of the 28-day treatment 
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period. All deaths were due to progression of liver disease – 2 in the placebo/low-dose group and 3 in 
the high-dose group.  For the remaining secondary efficacy endpoints, data was analysed up to the day 
7 time point, in view of the attrition of patient numbers at day 28.  
Changes in MELD score and CLIF-C ACLF score are presented in Table 4.  No statistically significant 
differences in these parameters were noted between the placebo/low-dose and high-dose groups at day 
7 (MELD -1 vs -1, CLIF-C ACLF 0.7 vs 0.8). Similarly, no specific changes in liver, kidney, brain or 
coagulation function were noted at day 7, by CLIF-C ACLF score parameter.  
Safety: As demonstrated in Figure 2, there were a total of 10 deaths across all treatment groups. There 
were 5 on-study deaths, 2 of which were during the one-month follow-up period following the full 
course of treatment, and a further 5 were registered via serious adverse event (SAE) reporting 
following discontinuation or study completion. All of these deaths were attributed to progressive liver 
disease. 
Adverse events (AEs) were reported by 17 of the 21 patients, of whom 13 patients reported SAEs. 
None of the SAEs was determined to be treatment-related. The only AEs deemed to be treatment-
related were nausea and vomiting which were reported by one placebo subject. The AEs and SAEs are 
presented in Table 5. 
 
Discussion 
Excessive cell death has been demonstrated to play a fundamental role in the progression of ACLF. 
Hepatocyte apoptosis has been shown to lead to Kupffer cell and hepatic stellate cell activation, and in 
pre-clinical models, apoptosis has been shown to promote inflammation and fibrogenesis(25-27). 
Caspase inhibitors have been shown to protect from liver injury in a rodent model of acute liver failure, 
and to attenuate inflammation and fibrosis in rodent models of cholestatic, alcohol and fatty liver 
disease(15, 16, 19). This study represents the first use of the caspase inhibitor emricasan in patients 
with decompensated cirrhosis.   
The primary objective of this study was to evaluate the pharmacokinetics, pharmacodynamics and 
safety of emricasan in this population.  All emricasan doses led to >10-fold higher levels of exposure 
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than observed in previous studies of either healthy volunteers or non-cirrhotic subjects with active 
HCV hepatitis, at the same doses, likely as consequence of porto-systemic shunting and associated 
bypass of first-pass hepatic uptake. Despite this, none of the reported adverse events were deemed to be 
treatment related, although, as discussed above, there was no attrition of subjects at later time points. 
The patient deaths and adverse events reported generally reflected the very severe liver disease in the 
study population. 
From a pharmacodynamic perspective, the 5 mg dose had negligible biologic effects upon the 
biomarkers measured (M30, M65 and caspase 3/7) in this study, and as a consequence, the placebo and 
5mg dose groups were merged for the analysis of secondary efficacy endpoints.   However, it is 
important to note that in non-cirrhotic subjects with active hepatitis C infection and presumably normal 
hepatic function, the 5 mg dose resulted in Cmax concentrations that were over 10-fold lower than 
observed in this study and yet decreased M30 levels ~50% (Study A8491010, unpublished data).  The 
5 mg dose has also been shown to significantly decrease ALT levels21,22.  The failure to see significant 
pharmacodynamic effects of the 5 mg dose in this study was not related to inadequate circulating drug 
concentrations but likely due to porto-systemic shunting and severe hepatocellular functional 
impairment. These factors, either separately or collectively, could result in low, sub-therapeutic 
hepatocyte levels of emricasan particularly since emricasan is a high first-pass extraction drug. 
Statistically significant reductions in the keratin fragments M30 were noted at day 2 and day 4 
following therapy when the 25 mg and 50 mg doses were analysed together, compared with the 
combined placebo and 5 mg group. However, this reduction was not sustained to 7 days or beyond. 
Potential contributing reasons for the failure to achieve statistical significance include insufficient 
power of the study due to the low recruitment of subjects, high attrition rates, poor compliance, and 
consequent shortened duration of follow-up for analysis.  
Despite the reduction in apoptosis markers, the results of this study failed to provide proof-of-concept 
support for the hypothesis of targeting apoptosis to prevent progression of ACLF. Although both the 25 
and 50 mg doses of emricasan decreased caspase 3/7 activity, proving that although emricasan was able 
to inhibit its biological target, only the 50 mg dose clearly decreased M30 levels, a marker of apoptosis, 
and there were no significant changes in MELD score, CLIF-C ACLF score or CLIF-C organ function 
score at 7 days. There are several possible reasons for this, including the above-noted comments of an 
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underpowered study population, shortened duration of analysis and sub-therapeutic hepatic drug levels 
due to porto-systemic shunting.  However, a further possibility is the complexity of modes of cell death 
involved in the progression of liver injury in ACLF. Aside from apoptosis, other forms of hepatocyte 
cell death have been described in ACLF, including autophagy, necroptosis and pyroptosis(28). The 
relative contribution of these, or predominant mode of cell death with different mechanisms of liver 
injury, remains to be established. Moreover, it remains unclear as to whether apoptosis is causal in the 
progression of ACLF or is an adaptive response to liver injury. In an open-label study, Frenette et al 
have recently reported that emricasan significantly decreased cleaved keratin levels and serum ALT 
levels in a population of patients with cirrhosis after six months of treatment at the 25 mg bid dose(29). 
Moreover, the subgroup of patients with a baseline MELD scores >15 had a significant improvement in 
MELD score, bilirubin and INR over the 3-month study period. Therefore, further, studies are 
warranted to address the efficacy of emricasan in advanced cirrhosis and ACLF. Amongst patients with 
hepatitis B related ACLF, levels of the M30 apoptosis marker were higher in survivors than non-
survivors, suggesting that apoptosis may also be an adaptive response to liver injury, possibly involved 
in liver regeneration(30).  
There are several weaknesses with this study. Only 23 patients were recruited from the planned study 
population of 60 subjects on the basis of the difficult enrolment. Additionally, the population was 
predominantly alcohol-related liver disease, thus limiting the applicability of the findings of this study 
to other aetiologies of cirrhosis. The follow-up data from this cohort was also limited, and less than 
half of the subjects completed 28 days of follow-up, hence limited conclusions can be drawn regarding 
longer-term secondary endpoints addressing the efficacy of emricasan in ACLF. Despite these 
limitations, the study conclusions are likely to be valid. 
In conclusion, this study demonstrates that emricasan is safe and well-tolerated in advanced liver 
disease, although hepatic drug levels may be sub-therapeutic due to porto-systemic shunting. Although 
reductions in caspase 3/7 activity and M30 component of the cytokeratin fragments were detected, this 
was not associated with any clinical benefit in this small study. The efficacy of emricasan in advanced 
cirrhosis and ACLF was not confirmed. Further mechanistic work is required to delineate the role of 
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Table 1.  Pharmacokinetic parameters 
 
Visit Parameter Emricasan 5 mg Emricasan 25 mg Emricasan 50 mg 
N Geo. Mean 
(CV%) 
N Geo. Mean 
(CV%) 
N Geo. Mean 
(CV%) 
Day 1 AUC0-8 (ng 
h/mL) 
5 275 (44) 5 1164 (45) 5 2441 (97) 
Cmax (ng/mL) 5 84.4 (44) 7 330 (48) 5 696 (117) 
tmax (h) 5 2.71 (65) 7 2.98 (89) 5 2.65 (119) 
t1/2 (h) 3 2.96 (89) 5 2.11 (33) 2 - 
Day 4 AUC0-8 (ng 
h/mL) 
4 224 (37) 5 1908 (33) 4 2362 (315) 
Cmax (ng/mL) 5 40.3 (32) 5 587 (34) 4 686 (194) 
tmax (h) 4 2.57 (146) 5 2.17 (85) 4 1.72 (1.08) 
t1/2 (h) 1 - 3 1.95 (7) 2 2.99 (150) 
 
 






High Dose  
(25, 50mg) 
N=11 
Organ n % n % 
  
Liver (≥ 12.0 mg/dL) 7 77.8% 9 81.8% 
Kidney (≥2.0 mg/dL or renal replacement) 0 0% 1 9.1% 
Brain (HE grade III or IV)  0 0% 0 0% 
Coagulation (INR >2.5 or 
platelet count <20x109/L)  5 83.3% 3 27.3% 
Circulation (vasopressor use) 1 11.1% 0 0% 
Respiratory (PaO/FiO2≤200 or 










Table 3: Changes from baseline in biomarkers M30, M65 and M30/65, and in MELD and CLIF-
C ACLF score 
 Placebo / 5mg 25mg / 50mg p-value 
n Median Range n Median Range  
cCK18 (M30) % change 
Day 2 7 -7.4 -40.0 / 18.3 11 -48.8 -70.7 / -4.4 0.017* 
Day 4 7 0 -43.5 /41.4 11 -41.9 -72.9 / -5.6 0.017* 
Day 7 8 -1.2 -43.6 / 75.8 11 -17.1 -66.3 / 97.4 0.342 
flCK18 (M65) % change 
Day 2 7 -9.7 -41.5 / 9.9 11 -31.0 -69.4 / 15.6 0.166 
Day 4 7 -4.7 -41.6 / 25.6 11 -25.4 -76.5 / 182.7 0.997 
Day 7 8 -3.7 -37.5 / 55.7 11 1.0 -60.7 / 164.6 0.430 
cCK18/flCK18 (M30/M65) 
Day 2 7 0.01 -0.12 / 0.06 11 -0.13 -0.26 / 0.57 0.624 
Day 4 7 0.04 -0.03 / 0.09 11 -0.08 -0.80 / 0.03 0.004* 
Day 7 8 -0.02 -0.07 / 0.09 11 -0.10 -0.75 / 0.87 0.427 
MELD  
Day 2 5 0 -5 / 3 11 0 -8 / 4 0.563 
Day 4 6 -2 -3 / 2 9 -2 -5 / 6 0.933 
Day 7 7 -1 -7 / 9 9 -1 -4 / 3 0.767 
CLIF-C ACLF Score† 
Day 2 3 -0.06 -0.11 / 2.28 6 0.62 -1.83 / 3.12 0.966 
Day 4 3 1.55 -2.90 / 2.44 8 1.67 -4.07 / 4.54 0.871 
Day 7 5 -1.47 -4.00 / 5.28 6 0.87 -2.99 / 7.30 0.466 
(*p<0.05, †where ACLF is present at baseline).   
Due to the distribution of the data for M30 and M65 the statistical analyses are based upon the change from 











Table 4: Changes from baseline in M30, M65, M30/65, MELD, and CLIF-C ACLF score 
 
Placebo / 5mg  
(N=9) 
25mg / 50mg  
(N=12)  













Day 2 7 
425 
(284 – 1999) 
-11.6 
(-32.0, +14.9) 11 
560 




Day 4 7 
717 
(297 – 2162) 
-3.5 
(-27.3, +28.2) 11 
516 




Day 7 8 
546.5 
(278 – 2162) 
-3.1 
(-30.3, 34.9) 11 
903 









(-30.6, +14.1) 11 
1945 




Day 4 7 
1237 
(548 – 2664) 
-14.1 
(-34.8, +13.1) 11 
1646 




Day 7 8 
1249 
(614 – 3098) 
+8.1 
(-31.2, +22.8) 11 
2555 















cCK18/flCK18 ratio (M30/M65) 





























































CLIF-C ACLF Score 































Due to the distribution of the data for M30 and M65 the statistical analyses are based upon the change from 
baseline in log-transformed data rather than percentage change from baseline, and results were back 




Table 5: Treatment-Related and All Causality Adverse Events, including Serious Adverse Events 
  Placebo (N=4) 5mg BID (N=5) 25mg BID (N=7) 50mg BID (N=5) All Subjects (N=21) 




Nausea 1 (25.0%) 0 0 0 0 0 0 0 0 1 
(4.8%) 





















0 0 7 
(33.3%) 
0 











0 0 1 
(20.0%) 




























Multiple-organ failure 1 (25.0%) 1 (25.0%) 1 
(20.0%) 































0 0 2 
(40.0%) 
1 (20.0%) 1 
(14.3%) 








Dyspnoea 2 (50.0%) 1 (25.0%) 0 0 1 
(14.3%) 





Supplementary Table 1:  Demography and Baseline Characteristics of Laboratory Data and Hepatic Biomarkers by Individual Randomized Treatment Groups 
 
  Placebo  (N=4) 
5 mg BID  
(N=5) 
25 mg BID  
(N=7) 
50 mg BID  
(N=5) 
Parameter n % n % n % n % 
Male  2 50% 3 60% 5 71.4% 3 60% 
Etiology of cirrhosis 
  Alcohol 4 100%  5  100% 6 85.7% 5 100% 
  Hepatitis C 0 0% 0 0% 1 14.3% 2 40% 
ACLF present at 
baseline 3 75% 4 80% 6 85.7% 4 80% 
Precipitating event for acute deterioration 
Bacterial Infection 1 33.3%  2  50%  3 50% 0 0% 
Alcohol 3 100% 3 75% 5 83.3% 5 100% 
GI haemorrhage 0 0% 0 0% 1 16.7% 0 0% 
HE Grade 
  0 
  1 


































Ascites  4  100% 4  80% 7 100% 5 100% 
 n Median Range n Median Range n Median Range n Median Range 
Age 4 53.5 34–59 5 49 41 – 60 7 50 30 - 58 5 61 42 - 71 
 21 
CLIF-C ACLF 
score 4 46.7 34.2  - 53.9 4 46.7 46.4 - 48.8 6 43.9 35.9 - 53.6 4 43.1 40.8 - 56.4 
MELD  4 26 19 – 31 5 29 27 – 33 6 29.5 28 - 34 5 23 22 - 36 
Laboratory Data 
  Creatinine 4 0.83 0.64-0.92 5 0.73 0.46 – 1.23 7 0.84 0.50 – 1.93 5 0.77 0.48 – 2.09 
  Bilirubin 4 15.77 4.7-21.0 5 14.7 11.3 -  33.4 7 23.3 14.1 – 34.7 5 17.7 2.2 – 33.2 
  INR  4 2.41 1.77-3.30 5 3.15 1.92 – 3.90 6 2.42 2.10 – 3.12 5 2.09 1.90 – 3.81 
  Platelet Count 4 67 39-133 3 60 25 – 274 5 119 57 - 155 4 144 29 - 210 
  Sodium 4 129 110-138 5 136 133 - 139 7 131 126 - 144 5 134 126 - 139 
  ALT 4 41.9 21.3-53.7 5 24.2 21.3 – 49.4 7 43.2 20.3 – 115.9 5 43.6 10.0 – 61.5 
  AST 4 124.5 65.5-201.7 5 69.7 42.0 – 152.9 7 89.8 74.8 – 251.7 5 100.5 23.2 – 189.1 
Hepatic Biomarkers 
  cCK18 (M30) 4 1085.5 240-3593 5 703 302 - 2162 7 1392 330 - 3593 5 919 395 – 1851 
  flCK18 (M65) 4 1887.5 507-3808 5 1345 876 - 2862 7 2819 277 - 3762 5 1946 705 – 6999 
 cCK18/flCK18 (M30/M65) 4 0.587 0.344-0.944 5 0.523 0.345-0.774 7 0.679 0.244 – 1.191 5 0.423 
0.216 – 
0.560 




Figure 1. Study design outline. 
Figure 2. CONSORT diagram of trial participants. 
†Two subjects met an exclusion criterion that was considered a major protocol deviation, but were 
randomized and included in all analyses as determined during a BDRM. 
*Reasons include: investigator decision to not continue with trial, and subject started on dialysis due to 
deteriorating renal function. 
**One patient had severe encephalopathy and was unable to swallow trial medications. 
***One patient had a severe upper GI bleed and another was unable to swallow trial medications. 
Admin. = administrative, AE = adverse event, BDRM = blind data review meeting, bd = twice daily, 
dec. = decision, FU = follow-up, invest. = investigator, N = number of subjects. 
 
Figure 3a. Change in cCK18 (M30) by treatment group. (Values are mean +/- SD) 
Figure 3b. Change in Caspase 3/7 by treatment group. (Values are mean +/- SD) 
 
 
